A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM.
Cleary JM, et al. Among authors: mcree aj.
Invest New Drugs. 2017 Feb;35(1):68-78. doi: 10.1007/s10637-016-0399-7. Epub 2016 Nov 16.
Invest New Drugs. 2017.
PMID: 27853996
Clinical Trial.